Colorectal cancer (CRC) represents one of the most urgent yet addressable oncology challenges confronting Latin America. In Mexico, digestive tract cancers remain a leading contributor to cancer mortality, while CRC continues to rank as the second-most common malignant neoplasm among Latino populations in the Americas.

This crisis stems less from a lack of therapeutic advances than from severe diagnostic bottlenecks. In several large regional hospital networks, the median interval from initial symptom onset to definitive treatment stretches to seven months. The longest portion of that delay occurs between initial clinical evaluation and diagnostic confirmation. When health systems rely on late stage symptomatic presentation, oncology care becomes reactive, expensive, and frequently palliative.

Overall ultra-processed food (UPF) consumption was not associated with increased colorectal cancer (CRC) incidence in a cohort of more than 400,000 U.S. adults, according to a study published October 15^th by Erikka Loftfield of the National Cancer Institute, U.S., and colleagues in the open access journal PLOS Medicine.

Researchers at the University of South Florida, Tampa General Hospital and Hokkaido University have uncovered an important mechanism behind immune evasion in metastatic colorectal cancer (mCRC). The finding challenges a 30-year-old theory in cancer research and identifies a molecular pathway that offers a new target for treatment.